2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Pagani O, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Goetz M, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer E, Ruepp B, Loi S, Coates A, Gelber R, Goldhirsch A, Regan M, Francis P, Group F. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. Journal Of Clinical Oncology 2022, 41: 1376-1382. PMID: 36521078, PMCID: PMC10419413, DOI: 10.1200/jco.22.01064.Peer-Reviewed Original ResearchConceptsDistant recurrence-free intervalOvarian function suppressionDisease-free survivalPrimary end pointOverall survivalAdjuvant exemestaneEnd pointBreast cancerReceptor-positive early breast cancerHuman epidermal growth factor receptorClinical trial updateYears of exemestaneOverall survival benefitHigh-risk patientsPremenopausal breast cancerRecurrence-free intervalEarly breast cancerGrade 3 tumorsRisk of recurrenceEpidermal growth factor receptorGrowth factor receptorSOFT trialTreat populationOvarian suppressionPremenopausal women
2011
OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.
Mayer E, Ligibel J, Burstein H, Peppercorn J, Miller K, Carey L, Dickler M, Mayer I, Forero A, Eng-Wong J, Pletcher P, Ryabin N, Gelman R, Wolff A, Winer E. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. Cancer Research 2011, 71: ot3-02-04-ot3-02-04. DOI: 10.1158/0008-5472.sabcs11-ot3-02-04.Peer-Reviewed Original ResearchPreoperative chemotherapyBreast cancerLifestyle interventionPhase II Randomized StudyAcceptable organ functionResidual invasive diseaseAdjuvant combination chemotherapyTaxane-based chemotherapyRecurrence-free survivalResidual breast cancerRisk of recurrenceFuture clinical trialsStructured exercise programImpact of exerciseAnti-angiogenic agentsUnmet medical needContribution of exerciseQuality of lifeYear BAdjuvant bevacizumabDFCI 05Eligible ptsLast surgeryNeoadjuvant chemotherapyPrimary endpoint
2007
A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer
Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Winer E, Burstein H. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. Journal Of Clinical Oncology 2007, 25: 561-561. DOI: 10.1200/jco.2007.25.18_suppl.561.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerAdjuvant bevacizumabAntiangiogenic therapyAnthracycline-containing neoadjuvant chemotherapyHigh-risk breast cancerAdjuvant antiangiogenic therapyResidual invasive carcinomaSingle-agent bevacizumabCycles of therapyTreatment-related toxicityChemotherapy-resistant diseasePhase II trialResidual breast cancerRisk of recurrenceNovel antiangiogenic therapiesEligible patientsMild arthralgiaAgent bevacizumabBevacizumab monotherapyII trialPrimary endpointMedian ageOngoing trialsOral chemotherapy
1997
Weight Gain in Women Diagnosed with Breast Cancer
WAHNEFRIED W, RIMER B, WINER E. Weight Gain in Women Diagnosed with Breast Cancer. Journal Of The Academy Of Nutrition And Dietetics 1997, 97: 519-529. PMID: 9145091, DOI: 10.1016/s0002-8223(97)00133-8.Peer-Reviewed Original ResearchConceptsBreast cancerWeight gainRisk of recurrenceQuality of lifeIntensity of treatmentQuantity of lifeMultiagent regimensPremenopausal womenMenopausal statusNodal statusWeight managementDietary intakePhysical activityHigh doseRate of metabolismCancerPatientsEffective interventionsDietetics practitionersLonger durationWomenDecrease survivalFurther studiesPsychosocial researchRecent findings